This Pharma is a Keeper

Written by GSCR Staff   
Monday, 14 January 2013 11:06

With a great deal of focus on the current flu outbreak we thought it would be timely to introduce an old-line generic drug company that could be an M&A target this year.

Lannett Company, Inc. (NYSE – LCI - $5.60) is a small pharmaceutical company that traces its roots to 1942. The Company’s current oral and topical drug portfolio includes generics related to a wide variety of ailments such as glaucoma, Parkinson’s disease, migraines, antibiotic, anesthetic, endometriosis, obesity, congestive heart failure, pain management, etc.

Investors should expect that progress in the introduction of new offerings in the fast-growing pain management segment and enhancing its R&D and production capabilities in this treatment category should be a boost to the Company’s already strong growth over the next year or so.

The stock has been on fire over the past 2 months, climbing from the $4.00 range to the present levels.  Current EPS estimates for the June 2013 year are $0.18 per share and EPS is expected to jump to $0.31 in its next fiscal year. It is possible that these estimates could be light given that LCI already reported 1Q13 fiscal EPS of $0.10 on a 25% rise in revenue from 1Q12.

The chart looks great and the stock is a hair under its year high. The only overhang we see is the recently revised shelf registration filed a month ago which would enable the Company and shareholders to sell as much as $64M in stock and debt securities. While management stated it has no plans to utilize this shelf right now, it clearly will down the road, in our view, which could increase the float and/or cause modest dilution.

Still, with an annual revenue-run rate in excess of $130M, nice profitability, a huge product portfolio, and an aged company and leadership, we would not be surprised to see LCI be snatched up this year.

If management continues to hit on all cylinders, LCI could be a $7.00 in a year’s time.

Disclosure: Goldman Small Cap Research analysts are neither long nor short these shares but may elect to purchase the stock within the next 48 hours.

Disclaimer:

This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com

Add comment
  • No comments found